There was a significantly higher @-year rate in the paclitaxel-eluting stent group than in the everolimus-eluting stent group of target-vessel failure ( P = @ ) , spontaneous myocardial infarction ( @ % vs. @ % , P = @ ) , stent thrombosis ( @ % vs. @ % , P = @ ) , target-vessel revascularization ( @ % vs. @ % , P = @ ) , and target-lesion revascularization ( @ % vs. @ % , P = @ ) .